Needham Reiterates Buy on Biogen, Maintains $294 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Biogen (NASDAQ:BIIB) and maintained a price target of $294.
May 22, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Biogen and maintained a price target of $294.
The reiteration of a Buy rating and the maintenance of a $294 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100